WASHINGTON, D.C. — In a significant escalation of the Trump administration’s campaign to reshape the landscape of pediatric healthcare, Vice President J.D. Vance and Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. have formally referred hundreds of hospitals and specialized gender clinics for criminal investigation and departmental audit. The referrals, which target institutions flagged in a blistering new HHS report titled “Wolves in White Coats,” signal a major shift in federal oversight of medical practices concerning gender-transition interventions for minors.
The move comes on the heels of a landmark administration policy decision to terminate all federal funding for what officials have termed “sex-rejecting procedures on children,” effectively ending the use of taxpayer dollars for gender-affirming surgeries and hormonal treatments in pediatric contexts.
The “Wolves in White Coats” Report: Allegations of Systemic Fraud
The catalyst for the administration’s action is a comprehensive HHS report that alleges a widespread pattern of insurance fraud embedded within the pediatric gender-affirming care industry. According to the document, investigators discovered that practitioners may have committed tens of millions of dollars in billing fraud over the past decade.
The report estimates that hospitals billed private and public insurers nearly $120 million for treatments linked to pediatric gender transition. Investigators identified hundreds of clinics and hospitals that allegedly utilized suspicious medical coding practices—a technique designed to secure insurance reimbursement for procedures that might otherwise be deemed ineligible for coverage.
“We are looking at a system that appears to have prioritized revenue growth over clinical integrity,” a senior administration official stated. “The billing patterns we have uncovered suggest a concerted effort to mischaracterize medical services to ensure that insurance companies, including Medicaid, foot the bill for procedures that are now subject to intense ethical and legal scrutiny.”
Vance Requests DOJ Intervention
Vice President J.D. Vance, spearheading the administration’s legal offensive, sent a formal letter to U.S. Attorney General Todd Blanche requesting a full-scale Department of Justice (DOJ) investigation into the providers named in the report. Vance’s request explicitly asks the DOJ to determine whether these institutions violated the Food, Drug, and Cosmetic Act, the False Claims Act, and federal conspiracy statutes.
In a series of posts on X, Vance did not mince words regarding his expectations for the outcome of these investigations. “More than just pushing these procedures on kids, hospitals and providers may have been defrauding Medicaid and private insurers by using misleading or fraudulent billing codes,” Vance wrote. “Those who intentionally engaged in this conduct—putting profit above the safety and well-being of minors—should go to prison.”
The Vice President’s call for criminal prosecution aligns with a broader DOJ probe into pediatric gender-transition clinics that was initiated in October 2025. This ongoing effort gained momentum following whistleblower testimonies, including high-profile claims from individuals at Texas Children’s Hospital who alleged that medical professionals performed experimental procedures on minors while simultaneously billing for unrelated, covered medical services to bypass insurance restrictions.
Kennedy Directs HHS Inspector General to Audit Billing Patterns
While the DOJ handles the criminal investigation, HHS Secretary Robert F. Kennedy Jr. has mobilized the HHS Office of Inspector General (OIG), headed by T. March Bell. Kennedy’s directive to Bell focuses on an exhaustive audit of an “objectively defined cohort of claims” that display anomalous billing patterns.
Kennedy identified four critical categories of irregular claims, which the HHS OIG is now tasked with auditing:
- Upcoding of Consultations: Investigating whether standard office visits were fraudulently coded as intensive surgical procedures.
- Misclassification of Hormonal Treatments: Examining the practice of labeling cross-sex hormones under codes for endocrine disorders to ensure reimbursement.
- Duplicate Billing: Identifying instances where clinics billed multiple insurers for the same clinical intervention.
- Phantom Services: Searching for evidence of billing for procedures or counseling sessions that were never performed.
“The public deserves transparency regarding how their tax dollars are being spent in the healthcare sector,” Kennedy stated in his referral letter. “Where there is smoke, there is often fire. We have identified a pattern of billing that defies standard medical practice, and it is the responsibility of this department to ensure that the integrity of our national health programs is not being compromised by profit-seeking entities.”
Legislative and State-Level Context
The federal crackdown follows a wave of legislative action at the state level, where at least 27 states have already enacted bans on gender-transition surgeries and hormonal treatments for patients under the age of 18.
Texas Attorney General Ken Paxton has been at the forefront of this battle, having filed multiple lawsuits against physicians and clinics accused of prescribing puberty blockers and cross-sex hormones to minors in direct defiance of state law. Meanwhile, Sen. Josh Hawley (R-MO) has intensified the pressure on the federal level, repeatedly urging the Trump administration to investigate Planned Parenthood’s role in the pediatric gender-transition business, alleging that the organization has become a primary driver of these services for minors.
The Ideological and Scientific Debate
The HHS report frames the pediatric gender industry not merely as a clinical service, but as a “strategic area of growth” for hospital networks. This perspective is mirrored in the work of several high-profile critics who argue that the rapid rise in adolescent gender dysphoria is a phenomenon driven by social contagion and clinical negligence rather than established medical necessity.
In her seminal book “Irreversible Damage,” author Abigail Shrier details the sudden surge in adolescent girls seeking gender transition, noting the lack of long-term studies on the psychological outcomes for these patients. These concerns have been bolstered by the work of Dr. Marty Makary, a former FDA official and author of “Blind Spots,” who highlighted the findings of the British National Health Service (NHS).
The NHS review, which ultimately led to the 2024 ban on puberty blockers outside of clinical trials, concluded that the evidence base for such treatments was “not supported by good evidence” and that the long-term safety profiles had not been adequately established. “We have been operating in a data vacuum for far too long,” Dr. Makary noted in recent testimony. “The medical establishment has been treating these patients as guinea pigs while simultaneously profiting from the transition process.”
Implications for the Healthcare Industry
The impact of these referrals is likely to be far-reaching. By targeting the billing and coding practices of major children’s hospitals, the administration is effectively weaponizing the financial regulatory system against the practice of pediatric transition.
Hospitals that are found to have violated the False Claims Act face the prospect of treble damages and potential exclusion from federal healthcare programs—a move that would be financially devastating for many institutions. Furthermore, the threat of criminal prosecution creates a chilling effect that could force clinics to cease operations immediately, even before the investigations reach a conclusion.
Industry experts are divided on the implications. Supporters of the move argue that it is a necessary corrective measure to protect children from irreversible medical procedures based on flawed or non-existent evidence. Critics, however, argue that the administration is politicizing medical billing and interfering with the doctor-patient relationship, warning that it could create a crisis of care for families who feel these treatments are medically necessary.
Status of the Referrals
As of this writing, there has been no public response from the Department of Justice or the HHS Office of Inspector General regarding the timeline of the proposed investigations. However, the scope of the referrals—covering hundreds of clinics and hospitals across the United States—suggests that this will be one of the most complex healthcare fraud investigations in the history of the Department of Health and Human Services.
With the administration doubling down on its commitment to end federal support for pediatric transition, the message from the White House is clear: the era of unchecked growth for the pediatric gender industry is coming to an abrupt and potentially litigious end. As the DOJ and HHS begin their review of the millions of billing records, the healthcare sector prepares for a protracted legal battle that will define the boundaries of pediatric medicine for years to come.
